Literature DB >> 29939303

Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.

Julie Dyall1, Elizabeth A Nelson2, Lisa Evans DeWald1, Rajarshi Guha3, Brit J Hart1, Huanying Zhou1, Elena Postnikova1, James Logue1, Walter M Vargas1, Robin Gross1, Julia Michelotti1, Nicole Deiuliis1, Richard S Bennett1, Ian Crozier1, Michael R Holbrook1, Patrick J Morris3, Carleen Klumpp-Thomas3, Crystal McKnight3, Tim Mierzwa3, Paul Shinn3, Pamela J Glass4, Lisa M Johansen5, Peter B Jahrling1,6, Lisa E Hensley1, Gene G Olinger1, Craig Thomas3, Judith M White2.   

Abstract

Background: A need to develop therapeutics to treat Ebola virus disease patients in remote and resource-challenged settings remains in the wake of the 2013-2016 epidemic in West Africa. Toward this goal, we screened drugs under consideration as treatment options and other drugs of interest, most being small molecules approved by the Food and Drug Administration. Drugs demonstrating in vitro antiviral activity were advanced for evaluation in combinations because of advantages often provided by drug cocktails.
Methods: Drugs were screened for blockade of Ebola virus infection in cultured cells. Twelve drugs were tested in all (78 pair-wise) combinations, and 3 were tested in a subset of combinations.
Results: Multiple synergistic drug pairs emerged, with the majority comprising 2 entry inhibitors. For the pairs of entry inhibitors studied, synergy was demonstrated at the level of virus entry into host cells. Highly synergistic pairs included aripiprazole/piperacetazine, sertraline/toremifene, sertraline/bepridil, and amodiaquine/clomiphene. Conclusions: Our study shows the feasibility of identifying pairs of approved drugs that synergistically block Ebola virus infection in cell cultures. We discuss our findings in terms of the theoretic ability of these or alternate combinations to reach therapeutic levels. Future research will assess selected combinations in small-animal models of Ebola virus disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29939303      PMCID: PMC6249579          DOI: 10.1093/infdis/jiy304

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Authors:  Lisa M Johansen; Lisa Evans DeWald; Charles J Shoemaker; Benjamin G Hoffstrom; Calli M Lear-Rooney; Andrea Stossel; Elizabeth Nelson; Sue E Delos; James A Simmons; Jill M Grenier; Laura T Pierce; Hassan Pajouhesh; Joseph Lehár; Lisa E Hensley; Pamela J Glass; Judith M White; Gene G Olinger
Journal:  Sci Transl Med       Date:  2015-06-03       Impact factor: 17.956

2.  Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Authors:  Xuelian Zhao; Katie A Howell; Shihua He; Jennifer M Brannan; Anna Z Wec; Edgar Davidson; Hannah L Turner; Chi-I Chiang; Lin Lei; J Maximilian Fels; Hong Vu; Sergey Shulenin; Ashley N Turonis; Ana I Kuehne; Guodong Liu; Mi Ta; Yimeng Wang; Christopher Sundling; Yongli Xiao; Jennifer S Spence; Benjamin J Doranz; Frederick W Holtsberg; Andrew B Ward; Kartik Chandran; John M Dye; Xiangguo Qiu; Yuxing Li; M Javad Aman
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

3.  Synergistic drug combination effectively blocks Ebola virus infection.

Authors:  Wei Sun; Shihua He; Carles Martínez-Romero; Jennifer Kouznetsova; Gregory Tawa; Miao Xu; Paul Shinn; Ethan Fisher; Yan Long; Omid Motabar; Shu Yang; Philip E Sanderson; Peter R Williamson; Adolfo García-Sastre; Xiangguo Qiu; Wei Zheng
Journal:  Antiviral Res       Date:  2016-11-24       Impact factor: 5.970

4.  Toxicology of ipecac: a review.

Authors:  B R Manno; J E Manno
Journal:  Clin Toxicol       Date:  1977       Impact factor: 4.467

5.  Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease.

Authors:  Etienne Gignoux; Andrew S Azman; Martin de Smet; Philippe Azuma; Moses Massaquoi; Dorian Job; Amanda Tiffany; Roberta Petrucci; Esther Sterk; Julien Potet; Motoi Suzuki; Andreas Kurth; Angela Cannas; Anne Bocquin; Thomas Strecker; Christopher Logue; Thomas Pottage; Constanze Yue; Jean-Clement Cabrol; Micaela Serafini; Iza Ciglenecki
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

6.  Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report.

Authors:  Gibrilla F Deen; Nathalie Broutet; Wenbo Xu; Barbara Knust; Foday R Sesay; Suzanna L R McDonald; Elizabeth Ervin; Jaclyn E Marrinan; Philippe Gaillard; Ndema Habib; Hongtu Liu; William Liu; Anna E Thorson; Francis Yamba; Thomas A Massaquoi; Faustin James; Archchun Ariyarajah; Christine Ross; Kyle Bernstein; Antoine Coursier; John Klena; Marylin Carino; Alie H Wurie; Yong Zhang; Marion S Dumbuya; Neetu Abad; Baimba Idriss; Teodora Wi; Sarah D Bennett; Tina Davies; Faiqa K Ebrahim; Elissa Meites; Dhamari Naidoo; Samuel J Smith; Patricia Ongpin; Tasneem Malik; Anshu Banerjee; Bobbie R Erickson; Yongjian Liu; Yang Liu; Ke Xu; Aaron Brault; Kara N Durski; Jörn Winter; Tara Sealy; Stuart T Nichol; Margaret Lamunu; James Bangura; Sihem Landoulsi; Amara Jambai; Oliver Morgan; Guizhen Wu; Mifang Liang; Qiudong Su; Yu Lan; Yanzhe Hao; Pierre Formenty; Ute Ströher; Foday Sahr
Journal:  N Engl J Med       Date:  2015-10-14       Impact factor: 91.245

7.  Systematic exploration of synergistic drug pairs.

Authors:  Murat Cokol; Hon Nian Chua; Murat Tasan; Beste Mutlu; Zohar B Weinstein; Yo Suzuki; Mehmet E Nergiz; Michael Costanzo; Anastasia Baryshnikova; Guri Giaever; Corey Nislow; Chad L Myers; Brenda J Andrews; Charles Boone; Frederick P Roth
Journal:  Mol Syst Biol       Date:  2011-11-08       Impact factor: 11.429

8.  A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.

Authors:  Stephen D S McCarthy; Beata Majchrzak-Kita; Trina Racine; Hannah N Kozlowski; Darren P Baker; Thomas Hoenen; Gary P Kobinger; Eleanor N Fish; Donald R Branch
Journal:  PLoS Negl Trop Dis       Date:  2016-01-11

9.  A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Authors:  Peter B Madrid; Sidharth Chopra; Ian D Manger; Lynne Gilfillan; Tiffany R Keepers; Amy C Shurtleff; Carol E Green; Lalitha V Iyer; Holli Hutcheson Dilks; Robert A Davey; Andrey A Kolokoltsov; Ricardo Carrion; Jean L Patterson; Sina Bavari; Rekha G Panchal; Travis K Warren; Jay B Wells; Walter H Moos; Raelyn L Burke; Mary J Tanga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 10.  Discovering Drugs for the Treatment of Ebola Virus.

Authors:  Sandra L Bixler; Allen J Duplantier; Sina Bavari
Journal:  Curr Treat Options Infect Dis       Date:  2017-08-04
View more
  26 in total

1.  Prediction of drug combination effects with a minimal set of experiments.

Authors:  Aleksandr Ianevski; Anil K Giri; Prson Gautam; Alexander Kononov; Swapnil Potdar; Jani Saarela; Krister Wennerberg; Tero Aittokallio
Journal:  Nat Mach Intell       Date:  2019-12-09

2.  Differential requirements for FcγR engagement by protective antibodies against Ebola virus.

Authors:  Stylianos Bournazos; David J DiLillo; Arthur J Goff; Pamela J Glass; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 3.  Improving therapy of severe infections through drug repurposing of synergistic combinations.

Authors:  Yu-Shan Cheng; Peter R Williamson; Wei Zheng
Journal:  Curr Opin Pharmacol       Date:  2019-08-24       Impact factor: 5.547

4.  Ebola Virus Entry Inhibitors.

Authors:  Ruikun Du; Qinghua Cui; Michael Caffrey; Lijun Rong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.

Authors:  C E Hulseberg; L Fénéant; K M Szymańska-de Wijs; N P Kessler; E A Nelson; C J Shoemaker; C S Schmaljohn; S J Polyak; J M White
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

6.  Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry.

Authors:  Jinwoo Lee; Alex J B Kreutzberger; Laura Odongo; Elizabeth A Nelson; David A Nyenhuis; Volker Kiessling; Binyong Liang; David S Cafiso; Judith M White; Lukas K Tamm
Journal:  Nat Struct Mol Biol       Date:  2021-01-18       Impact factor: 15.369

Review 7.  Drug combination therapy for emerging viral diseases.

Authors:  Zeenat A Shyr; Yu-Shan Cheng; Donald C Lo; Wei Zheng
Journal:  Drug Discov Today       Date:  2021-05-21       Impact factor: 7.851

8.  Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection.

Authors:  Kai J Rogers; Olena Shtanko; Laura L Stunz; Laura N Mallinger; Tina Arkee; Megan E Schmidt; Dana Bohan; Bethany Brunton; Judith M White; Steve M Varga; Noah S Butler; Gail A Bishop; Wendy Maury
Journal:  J Leukoc Biol       Date:  2020-05-22       Impact factor: 4.962

Review 9.  Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease.

Authors:  Marhiah C Montoya; Damian J Krysan
Journal:  mBio       Date:  2018-12-18       Impact factor: 7.867

10.  The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry.

Authors:  Chiara Fedeli; Hector Moreno; Stefan Kunz
Journal:  Viruses       Date:  2020-08-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.